Loading...
XASXNEU
Market cap970mUSD
Dec 20, Last price  
12.14AUD
1D
-3.19%
1Q
-14.45%
Jan 2017
946.55%
IPO
94.32%
Name

Neuren Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XASX:NEU chart
P/E
9.88
P/S
6.69
EPS
1.23
Div Yield, %
0.00%
Shrs. gr., 5y
5.56%
Rev. gr., 5y
75.35%
Revenues
232m
+1,493.66%
1,399,780429,665172,967944,1602,274,3625,003,2374,648,090004,794,0002,931,0001,673,0003,150,000631,00013,990,000495,000717,0003,197,00014,553,000231,925,000
Net income
157m
+85,270.11%
0000099,5620000-8,297,000-13,397,000-12,014,0003,288,0003,073,000-10,816,000-9,193,000-7,794,000184,000157,081,000
CFO
185m
+5,038.23%
0000000000-6,410,000-12,731,000-12,378,000-5,590,0006,408,000-11,719,000-8,077,999-9,970,0003,599,000184,925,000
Earnings
Jan 29, 2025

Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
URL
https://www.neurenpharma.com/
IPO date
Feb 03, 2005
Employees
Domiciled in
AU
Incorporated in
NZ

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
231,925
1,493.66%
14,553
355.21%
3,197
345.89%
Cost of revenue
59,448
16,149
11,430
Unusual Expense (Income)
NOPBT
172,477
(1,596)
(8,233)
NOPBT Margin
74.37%
Operating Taxes
48,059
(864)
(3,197)
Tax Rate
27.86%
NOPAT
124,418
(732)
(5,036)
Net income
157,081
85,270.11%
184
-102.36%
(7,794)
-15.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,619
(4)
21,069
BB yield
-0.11%
0.00%
-4.75%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(228,539)
(40,180)
(36,783)
Cash flow
Cash from operating activities
184,925
3,599
(9,970)
CAPEX
(40)
(19)
(10)
Cash from investing activities
(211,485)
(19)
(10)
Cash from financing activities
3,619
(2)
22,175
FCF
112,811
329
(7,494)
Balance
Cash
228,539
40,180
36,783
Long term investments
Excess cash
216,943
39,452
36,623
Stockholders' equity
205,207
41,589
39,253
Invested Capital
2,137
2,630
ROIC
ROCE
84.05%
EV
Common stock shares outstanding
130,768
128,909
117,770
Price
24.97
214.09%
7.95
110.88%
3.77
193.39%
Market cap
3,265,289
218.62%
1,024,827
130.82%
443,993
222.74%
EV
3,036,750
984,647
407,210
EBITDA
172,494
(1,586)
(8,225)
EV/EBITDA
17.60
Interest
Interest/NOPBT